Free Research Report Download:
The Cancer Market Outlook To 2014
Free Pharmaceutical Market Research Reports
Biotechnology
Corporate & Fiscal
Drug Delivery
Health Products
Hospital Markets
Indication Areas
Medical Devices
Prescription Medicines
R&D
Custom Research
Pharmaceutical Events & Conferences
Contact
Terms & Conditions
Privacy
Home >
The Ophthalmic Pharmaceutical Market Outlook To 2014: Competitive landscape, pipeline analysis, growth opportunities and market forecasts
Report
Published: September 2009
Pages: 158
Tables: For full details, please email keithw@cmsinfo.com
From: GBP 2396.88 Buy Now!
Research from: pharmaceuticalmarketresearch
Sector: Indication Areas
Introduction
The $13.5bn global ophthalmic pharmaceutical market demonstrated low double-digit y-o-y growth in 2008. The emergence of treatment strategies for age-macular degeneration and the subsequent therapeutic and commercial success of Lucentis has led to a substantial rise in overall size of the market while signaling the lucrative and expanding sector within ophthalmology. However, the market faces a patent cliff post 2010 due to patent expiries of class-leading products in anti-glaucoma, ocular anti-allergic and anti-infective/anti-inflammatory therapies. Subsequent generic incursion coupled with the increasing legislative priority towards healthcare reform across the globe will hurt market expansion and growth of ophthalmic franchises of leading pharmaceutical companies. Driven by good efficacy, Roche/Genentech’s Lucentis and Allergan/Inspire’s Restasis is expected to dominate the treatment of wet AMD and dry eye markets respectively. However Business Insights expect worldwide sales of ophthalmology treatments to remain roughly flat during 2008-14.
Key findings
• The ophthalmic pharmaceutical market registered sales of $13.5bn in 2008, at a y-o-y increase of 13.3%. The top ten ophthalmic brands accounted for $6.6bn sales or 49.0% share of the market in 2008.
• Anti-glaucoma preparations formed the largest category in 2008, posting $5.2bn sales. The segment grew at 11.0% y-o-y, accounting for 38.7% market share. Pfizer’s Xalatan dominated this segment while delivering sales of $1.6bn. The segment is expected to post a CAGR of -9.7% during 2008-2014.
• Ocular antineovascularization preparations, used for the treatment of wet AMD, accounted for $1.8bn in sales during 2008. The segment captured 13.4% of the market, while registering a robust y-o-y growth of 29.8%. Roche/Novartis’ Lucentis dominated the market with $1.6bn sales during the same year. The segment will be one of the major growth drivers for the market with CAGR of 6.7% during 2008-14.
Key features of this report
• Estimation of target population in leading ophthalmic indications that offer high commercial prospects such as cataract, glaucoma, age-related macular degeneration (AMD), diabetic retinopathy and diabetic macular edema (DME) and dry eye syndrome in the ophthalmic pharmaceutical sector.
• Company analysis and market share of the top eight players in the ophthalmic pharmaceutical market: Alcon, Allergan, Pfizer, Novartis, Roche, Merck, Santen Seiyaku and Bausch & Lomb.
• Overview of key events in the ophthalmic pharmaceutical market that have impacted treatment trends and sales potential across indications.
• In-depth analysis of the ophthalmic pharmaceutical pipeline
Use this report to
• Quantify the epidemiological status of cataract, glaucoma, AMD and dry eye syndrome in the US, 5EU and Japan.
• Understand therapy segments with the greatest franchise growth potential and understand the growth drivers.
• Compare the franchises of top ophthalmic pharmaceutical players across major indications, and evaluate how market share of leading companies such as Alcon, Allergan, Pfizer, Novartis, Roche, Merck, Santen Seiyaku and Bausch & Lomb will evolve over the next five years.
Discover
• What will be the major growth indications and the accompanying growth drivers in the ophthalmic pharmaceutical market over 2008–14?
• What are the current trends within the major segments such as glaucoma, retinal disorders (AMD, DME, etc.), dry eye syndrome, ophthalmic infections and inflammation, etc.?
• What are the most promising ophthalmic products in clinical development and their forecast commercial potential through 2014?
• Which companies are best positioned to succeed in the ophthalmic pharmaceutical market over the period 2008–14?
The $13.5bn global ophthalmic pharmaceutical market demonstrated low double-digit y-o-y growth in 2008. The emergence of treatment strategies for age-macular degeneration and the subsequent therapeutic and commercial success of Lucentis has led to a substantial rise in overall size of the market while signaling the lucrative and expanding sector within ophthalmology. However, the market faces a patent cliff post 2010 due to patent expiries of class-leading products in anti-glaucoma, ocular anti-allergic and anti-infective/anti-inflammatory therapies. Subsequent generic incursion coupled with the increasing legislative priority towards healthcare reform across the globe will hurt market expansion and growth of ophthalmic franchises of leading pharmaceutical companies. Driven by good efficacy, Roche/Genentech’s Lucentis and Allergan/Inspire’s Restasis is expected to dominate the treatment of wet AMD and dry eye markets respectively. However Business Insights expect worldwide sales of ophthalmology treatments to remain roughly flat during 2008-14.
Key findings
• The ophthalmic pharmaceutical market registered sales of $13.5bn in 2008, at a y-o-y increase of 13.3%. The top ten ophthalmic brands accounted for $6.6bn sales or 49.0% share of the market in 2008.
• Anti-glaucoma preparations formed the largest category in 2008, posting $5.2bn sales. The segment grew at 11.0% y-o-y, accounting for 38.7% market share. Pfizer’s Xalatan dominated this segment while delivering sales of $1.6bn. The segment is expected to post a CAGR of -9.7% during 2008-2014.
• Ocular antineovascularization preparations, used for the treatment of wet AMD, accounted for $1.8bn in sales during 2008. The segment captured 13.4% of the market, while registering a robust y-o-y growth of 29.8%. Roche/Novartis’ Lucentis dominated the market with $1.6bn sales during the same year. The segment will be one of the major growth drivers for the market with CAGR of 6.7% during 2008-14.
Key features of this report
• Estimation of target population in leading ophthalmic indications that offer high commercial prospects such as cataract, glaucoma, age-related macular degeneration (AMD), diabetic retinopathy and diabetic macular edema (DME) and dry eye syndrome in the ophthalmic pharmaceutical sector.
• Company analysis and market share of the top eight players in the ophthalmic pharmaceutical market: Alcon, Allergan, Pfizer, Novartis, Roche, Merck, Santen Seiyaku and Bausch & Lomb.
• Overview of key events in the ophthalmic pharmaceutical market that have impacted treatment trends and sales potential across indications.
• In-depth analysis of the ophthalmic pharmaceutical pipeline
Use this report to
• Quantify the epidemiological status of cataract, glaucoma, AMD and dry eye syndrome in the US, 5EU and Japan.
• Understand therapy segments with the greatest franchise growth potential and understand the growth drivers.
• Compare the franchises of top ophthalmic pharmaceutical players across major indications, and evaluate how market share of leading companies such as Alcon, Allergan, Pfizer, Novartis, Roche, Merck, Santen Seiyaku and Bausch & Lomb will evolve over the next five years.
Discover
• What will be the major growth indications and the accompanying growth drivers in the ophthalmic pharmaceutical market over 2008–14?
• What are the current trends within the major segments such as glaucoma, retinal disorders (AMD, DME, etc.), dry eye syndrome, ophthalmic infections and inflammation, etc.?
• What are the most promising ophthalmic products in clinical development and their forecast commercial potential through 2014?
• Which companies are best positioned to succeed in the ophthalmic pharmaceutical market over the period 2008–14?